Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials
J Thorac Dis
.
2018 Feb;10(2):617-620.
doi: 10.21037/jtd.2018.01.105.
Authors
Sha'Shonda L Revels
1
,
Jay M Lee
1
Affiliation
1
Division of Thoracic Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.
PMID:
29607123
PMCID:
PMC5864582
DOI:
10.21037/jtd.2018.01.105
No abstract available
Publication types
Editorial
Comment